<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540735</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2006-01</org_study_id>
    <nct_id>NCT00540735</nct_id>
  </id_info>
  <brief_title>Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas</brief_title>
  <acronym>CK/PDT</acronym>
  <official_title>Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas - A Prospective, Multicentric and Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unresectable type III or IV cholangiocarcinoma has a very bad prognosis; survival median&#xD;
      ranges between 6 and 9 months.&#xD;
&#xD;
      Survival depends on biliary drainage quality, obtained by plastic or metallic prothesis&#xD;
      setting up in one or several hepatic segments.&#xD;
&#xD;
      Radiotherapy and/or chemotherapy didn't prove yet their efficiency on survival. In France,&#xD;
      gemcitabin is recommended by the French Digestive Oncology Federation in metastatic tumours,&#xD;
      in monotherapy or associated with cisplatin or oxaliplatin (Gemox) for patients in good&#xD;
      general condition.&#xD;
&#xD;
      Photodynamic therapy has shown in 3 prospective studies - one randomized - with small patient&#xD;
      series, a significative efficiency on survival and quality of life of treated patients, in&#xD;
      comparison with historical series, or patients' groups whose biliary drainage was in most&#xD;
      cases unefficient.&#xD;
&#xD;
      A new randomized study, including patients whose biliary drainage is efficient and comparing&#xD;
      their becoming when they are treated by PDT in addition to current practice, or only by&#xD;
      current practice, seems to be justified.&#xD;
&#xD;
      The principal objective of this study is to evaluate the efficiency of PDT with Photofrin® on&#xD;
      patients with unresectable type III or IV cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Big difficulties to enroll patients&#xD;
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date>November 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' survival compared between both groups : PDT and non-PDT.</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>80</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obtention of a written informed consent.&#xD;
&#xD;
          -  Patient over 18.&#xD;
&#xD;
          -  Patient with a type III or IV (according to Bismuth classification) histologically&#xD;
             proved cholangiocarcinoma ; histologic diagnosis must be proved by biliary brushing,&#xD;
             bile cytology, endobiliary biopsy under scope control with pediatric pliers, or by&#xD;
             cytologic puncture under scan or echoendscopic control.&#xD;
&#xD;
          -  Patient with Karnofsky score ≥ 50 %&#xD;
&#xD;
          -  Patient with an efficient initial biliary drainage with prothesis.&#xD;
&#xD;
          -  Cancer classified maximum T3N1M1, but only with intrahepatic metastasis occupying less&#xD;
             than 25% of hepatic parenchyme (according to TNM cancer classification of extrahepatic&#xD;
             biliary ducts' cancers).&#xD;
&#xD;
          -  Patient capable of fill in the quality of life questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No written informed consent.&#xD;
&#xD;
          -  Type I and II cholangiocarcinoma according to Bismuth classification.&#xD;
&#xD;
          -  Patients with ASA score 4.&#xD;
&#xD;
          -  Patients with clinical and biological signs of biliary infection.&#xD;
&#xD;
          -  Patients with a severe visceral disease other than cholangiocarcinoma.&#xD;
&#xD;
          -  Patients without an efficient initial biliary drainage.&#xD;
&#xD;
          -  Patients with extrahepatic visceral metastasis, except perihilar ganglionic metastasis&#xD;
             classified T4N1M+ according to TNM classification.&#xD;
&#xD;
          -  Patients whose cholangiocarcinoma has already been resected.&#xD;
&#xD;
          -  Patients under or already treated by radiotherapy or chemotherapy treatment for&#xD;
             cholangiocarcinoma.&#xD;
&#xD;
          -  Patients first treated with metallic prothesis.&#xD;
&#xD;
          -  Patients with a contraindication to MRI.&#xD;
&#xD;
          -  Patients with porphyria or hypersensibility to porphyrins.&#xD;
&#xD;
          -  Patient treated by a non authorized treatment at the time of inclusion.&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding women.&#xD;
&#xD;
          -  Non menopaused woman without an efficient contraception.&#xD;
&#xD;
          -  Patient under 18.&#xD;
&#xD;
          -  Person over 18 under protection according to French Public Health Code.&#xD;
&#xD;
          -  Person not affiliated to a social security regimen, or benefiting from such a regimen.&#xD;
&#xD;
          -  Person in a exclusion period of another biomedical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Boyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92 118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94 010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94 275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59 037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Lyon</city>
        <zip>69 003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13 385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Marseille Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13 915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57 038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Trocadéro</name>
      <address>
        <city>Paris</city>
        <zip>75 116</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75 679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86 021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76 031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31 059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31 059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

